Patents by Inventor John Sigurd Svendsen

John Sigurd Svendsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10927106
    Abstract: The present invention relates to compounds of Formula (I), which are DYRK1A and/or DYRK1B inhibitors, and their use in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), metabolic disorders such as Metabolic Syndrome or diabetes mellitus, and cancer.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: February 23, 2021
    Assignee: PHARMASUM THERAPEUTICS AS
    Inventors: John Sigurd Svendsen, Wenche Stensen, Roderick Alan Porter
  • Publication number: 20190375742
    Abstract: The present invention relates to compounds of Formula (I), which are DYRK1A and/or DYRK1B inhibitors, and their use in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), metabolic disorders such as Metabolic Syndrome or diabetes mellitus, and cancer.
    Type: Application
    Filed: October 12, 2017
    Publication date: December 12, 2019
    Inventors: John Sigurd Svendsen, Wenche Stensen, Roderick Alan Porter
  • Patent number: 10287320
    Abstract: The present invention provides a peptide which: (i) consists of 10 to 16 amino acids; (ii) has at least 8 cationic amino acids with either (a) a side chain comprising a guanidinium group, or (b) a side chain comprising an amino group, of which no more than 7 are consecutive; and (iii) has 2 or 3 tryptophan residues which are not both, or not all, consecutive, said peptide optionally in the form of a salt, ester or amide, or a peptidomimetic of said peptide. The invention further relates to pharmaceutical compositions containing these compounds, the use of these compounds in therapy, particularly as anti-tumor (e.g. anti-lymphoma) agents and non-therapeutic uses of these compounds.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: May 14, 2019
    Assignee: Universitetet i Tromsø—Norges Arktiske Universit
    Inventors: John Sigurd Svendsen, Øystein Rekdal, Johannes Eksteen
  • Publication number: 20170073372
    Abstract: The present invention provides a peptide which: (i) consists of 10 to 16 amino acids; (ii) has at least 8 cationic amino acids with either (a) a side chain comprising a guanidinium group, or (b) a side chain comprising an amino group, of which no more than 7 are consecutive; and (iii) has 2 or 3 tryptophan residues which are not both, or not all, consecutive, said peptide optionally in the form of a salt, ester or amide, or a peptidomimetic of said peptide. The invention further relates to pharmaceutical compositions containing these compounds, the use of these compounds in therapy, particularly as anti-tumour (e.g. anti-lymphoma) agents and non-therapeutic uses of these compounds.
    Type: Application
    Filed: February 4, 2015
    Publication date: March 16, 2017
    Inventors: John Sigurd SVENDSEN, Oystein REKDAL, Johannes EKSTEEN
  • Patent number: 9556223
    Abstract: The present invention relates to a compound of formula (I) AA-AA-AA-R1—R2 (I) wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; R1 is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group, which group may incorporate up to 2 heteroatoms selected from N, O and S; and R2 is an aliphatic moiety having 2-20 non-hydrogen atoms, said moiety being linear, branched or cyclic. The invention further relates to formulations containing these compounds, solid supports having these compounds attached thereto, the use of these compounds in therapy, particularly as antimicrobial, anti-tumor or anti-biofilm agents and non-therapeutic uses of these compounds, particularly their use in inhibiting biofilm formation or removing a biofilm.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: January 31, 2017
    Assignee: LYTIX BIOPHARMA AS
    Inventors: Wenche Stensen, Frederick Alan Leeson, Øystein Rekdal, John Sigurd Svendsen
  • Publication number: 20160176923
    Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.
    Type: Application
    Filed: December 14, 2015
    Publication date: June 23, 2016
    Inventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
  • Patent number: 9241968
    Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumor agents.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: January 26, 2016
    Assignee: Lytix Biopharma AS
    Inventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
  • Patent number: 9212202
    Abstract: The present invention relates to a method of improving the resistance of a peptide or peptidomimetic to degradation by trypsin which comprises incorporating into said peptide or peptidomimetic a C-terminal capping group of formula (I): X—Y—Z (I) wherein X is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group which group may incorporate up to 2 heteroatoms selected from N, O and S; Y represents a group selected from —Ra—Rb—, —Ra—Rb—Rb,- and —Rb—Rb—Ra— wherein Ra is C, O, S or N, and Rb is C; each of Ra and Rb, may be substituted by C1-C4 alkyl groups or unsubstituted; and Z is a group comprising 1 to 3 cyclic groups each of 5 or 6 non-hydrogen atoms, 2 or more of the cyclic groups may be fused and one or more of the cyclic groups may be substituted; the Z. moiety incorporates a maximum of 15 non-hydrogen atoms; and wherein the bond between Y and Z is a covalent bond between Ra or Rb of Y and a non-hydrogen atom of one of the cyclic groups of Z.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: December 15, 2015
    Assignee: Lytix Biopharma AS
    Inventors: Wenche Stensen, Oystein Rekdal, John Sigurd Svendsen
  • Patent number: 9115169
    Abstract: The invention provides a method of treating tumors by adminstering to a human or animal patient an effective amount of a molecule of 2 to 4 amino acids or equivalent subunits in length, which incorporates a bulky and lipophilic group comprising at least 13 non-hydrogen atoms and containing no more than 2 polar functional groups, in which the bulky and lipophilic group incorporates one or more closed rings of 5 or more non-hydrogen atoms, and in which the molecule further has at least two more cationic than anionic moieties.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: August 25, 2015
    Assignee: Lytix Biopharma AS
    Inventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
  • Patent number: 9109048
    Abstract: The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoral agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumor growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: August 18, 2015
    Assignee: LYTIX BIOPHARMA AS
    Inventors: Liv Tone Eliassen, Gerd Berge, Baldur Sveinbjørnsson, John Sigurd Svendsen, Øystein Rekdal
  • Patent number: 9085608
    Abstract: The present invention relates to a peptide or peptidomimetic for use in the treatment of a biofilm-associated infection in a subject, wherein said peptide or peptidomimetic a) carries a net positive charge, —b) is 1 to 6 amino acids in length or is an equivalently sized peptidomimetic; and c) is amphipathic in nature, having one or more lipophilic groups, one of said lipophilic groups comprising at least 7 non-hydrogen atoms.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: July 21, 2015
    Assignee: LYTIX BIOPHARMA AS
    Inventors: Wenche Stensen, Frederick Alan Leeson, Stig Olov Magnus Engqvist, Trond Flægstad, Øystein Rekdal, John Sigurd Svendsen
  • Publication number: 20150018311
    Abstract: The present invention relates to compounds of Formula (I) wherein R1 and R3 are hydrogen; R2 and R4, which may be the same or different, are hydrogen, a C1-6 alkyl group optionally substituted by an aryl group which may itself be substituted, the substituent group including an alkyl group or an —OR group in which R is a C1-3 alkyl group, with one or more hydrogen atoms optionally replaced with a halogen atom; or an aryl group which may be substituted, the substituent group including an alkyl group or an —OR group in which R is a C1-3 alkyl group, with one or more hydrogen atoms optionally replaced with a halogen atom; with the proviso that R2 and R4 are not both hydrogen; the atom of R4 which is attached to C? is either a saturated carbon atom or an atom which is part of a 1 substituted aromatic ring; (AA)0-5 is an amino acid, amino acid derivative, peptide of up to 5 amino acids or a peptidomimetic thereof which optionally incorporates an N-terminal capping group, when the group is (AA)0 an N-terminal cappin
    Type: Application
    Filed: January 8, 2013
    Publication date: January 15, 2015
    Applicant: University of Tromsø
    Inventors: Tore Lejon, John Sigurd Svendsen, Alexey Gorovoy, Olga Gozhina
  • Publication number: 20140037657
    Abstract: The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoral agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumor growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject.
    Type: Application
    Filed: August 14, 2012
    Publication date: February 6, 2014
    Applicant: LYTIX BIOPHARMA AS
    Inventors: Liv Tone Eliassen, Gerd Berge, Baldur Sveinbjornsson, John Sigurd Svendsen, Oystein Rekdal
  • Patent number: 8598114
    Abstract: The present invention relates to a compound of formula (I) AA-AA-AA-X—Y—Z wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; X is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group which group may incorporate up to 2 heteroatoms selected from N, O and S; Y represents a group selected from —Ra—Rb—, —Ra—Rb—Rb— and —Rb—Rb—Ra— wherein Ra is C, O, S or N, and Rb is C; each of Ra and Rb may be substituted by C1-C4 alkyl groups or unsubstituted; and Z is a group comprising 1 to 3 cyclic groups each of 5 or 6 non-hydrogen atoms, 2 or more of the cyclic groups may be fused and one or more of the cyclic groups may be substituted; the Z moiety incorporates a maximum of 15 non-hydrogen atoms; and wherein the bond between Y and Z is a covalent bond between Ra or Rb of Y and a non-hydrogen atom of one of the cyclic groups of Z.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: December 3, 2013
    Assignee: Lytix Biopharma AS
    Inventors: Wenche Stensen, Bengt Erick Haug, Oystein Rekdal, John Sigurd Svendsen
  • Patent number: 8283315
    Abstract: The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoral agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumor growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: October 9, 2012
    Assignee: Lytix Biopharma AS
    Inventors: Liv Tone Eliassen, Gerd Berge, Baldur Sveinbjørnsson, John Sigurd Svendsen, Øystein Rekdal
  • Publication number: 20120108520
    Abstract: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.
    Type: Application
    Filed: September 22, 2011
    Publication date: May 3, 2012
    Applicant: LYTIX BIOPHARMA AS
    Inventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
  • Patent number: 8143211
    Abstract: The present invention provides a cytotoxic 7 to 25-mer peptide with three or more cationic residues which has one or more non-generic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them, and their use as medicaments, particularly as antibacterial or antitumor agents.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: March 27, 2012
    Assignee: Lytix Biopharma AS
    Inventors: John Sigurd Svendsen, Øystein Rekdal, Baldur Sveinbjørnsson, Lars Vorland
  • Publication number: 20110318364
    Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.
    Type: Application
    Filed: September 11, 2009
    Publication date: December 29, 2011
    Applicant: LYTIX BIOPHARMA AS
    Inventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
  • Patent number: 8048852
    Abstract: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilizing microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: November 1, 2011
    Assignee: Lytix Biopharma AS
    Inventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
  • Publication number: 20110236453
    Abstract: The present invention relates to a peptide or peptidomimetic for use in the treatment of a biofilm-associated infection in a subject, wherein said peptide or peptidomimetic a) carries a net positive charge, b) is 1 to 6 amino acids in length or is an equivalently sized peptidomimetic; and c) is amphipathic in nature, having one or more lipophilic groups, one of said lipophilic groups comprising at least 7 non-hydrogen atoms.
    Type: Application
    Filed: October 2, 2009
    Publication date: September 29, 2011
    Applicant: LYTIX BIOPHARMA AS
    Inventors: Wenche Stensen, Frederick Alan Leeson, Stig Olov Magnus Engqvist, Trond Flægstad, Øystein Rekdal, John Sigurd Svendsen